Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

1.

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Parilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL.

Blood. 2014 Jun 3. pii: blood-2014-04-571091. [Epub ahead of print]

PMID:
24894770
[PubMed - as supplied by publisher]
2.

PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data.

Wang C, Evans JM, Bhagwate AV, Prodduturi N, Sarangi V, Middha M, Sicotte H, Vedell PT, Hart SN, Oliver GR, Kocher JP, Maurer MJ, Novak AJ, Slager SL, Cerhan JR, Asmann YW.

Bioinformatics. 2014 May 29. pii: btu363. [Epub ahead of print]

PMID:
24876377
[PubMed - as supplied by publisher]
Free Article
3.

Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.

Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, Wang C, Tyrer J, Song H, deFazio A, Johnatty SE, Doherty JA, Phelan CM, Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaarde B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubiłski J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, Vergote I, Lambrechts S, Despierre E, Garcia-Closas M, Yang H, Brinton LA, Spiewankiewicz B, Rzepecka IK, Dansonka-Mieszkowska A, Seibold P, Rudolph A, Paddock LE, Orlow I, Lundvall L, Olson SH, Hogdall CK, Schwaab I, du Bois A, Harter P, Flanagan JM, Brown R, Paul J, Ekici AB, Beckmann MW, Hein A, Eccles D, Lurie G, Hays LE, Bean YT, Pejovic T, Goodman MT, Campbell I, Fasching PA, Konecny G, Kaye SB, Heitz F, Hogdall E, Bandera EV, Chang-Claude J, Kupryjanczyk J, Wentzensen N, Lambrechts D, Karlan BY, Whittemore AS, Culver HA, Gronwald J, Levine DA, Kjaer SK, Menon U, Schildkraut JM, Pearce CL, Cramer DW, Rossing MA, Chenevix-Trench G; AOCS group; ACS, Pharoah PD, Gayther SA, Ness RB, Odunsi K, Sucheston LE, Knutson KL, Goode EL.

Cancer Immunol Res. 2014 Apr;2(4):332-40. doi: 10.1158/2326-6066.CIR-13-0136. Epub 2014 Jan 27.

PMID:
24764580
[PubMed - in process]
4.

Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors.

Rausch Osian S, Leal AD, Allmer C, Maurer MJ, Nowakowski G, Inwards DJ, Macon WR, Ehlers SL, Weiner GJ, Habermann TM, Cerhan JR, Thompson CA.

Leuk Lymphoma. 2014 Jun 27:1-6. [Epub ahead of print]

PMID:
24745936
[PubMed - as supplied by publisher]
5.

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.

Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM.

Am J Hematol. 2014 Jun;89(6):639-45. doi: 10.1002/ajh.23709. Epub 2014 Apr 12.

PMID:
24633940
[PubMed - in process]
6.

Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.

Hsi ED, Said J, Macon WR, Rodig SJ, Ondrejka SL, Gascoyne RD, Morgan EA, Dorfman DM, Maurer MJ, Dogan A.

Am J Surg Pathol. 2014 Jun;38(6):768-75. doi: 10.1097/PAS.0000000000000188.

PMID:
24618604
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR.

J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18.

PMID:
24550425
[PubMed - indexed for MEDLINE]
8.

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P.

Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611. Epub 2014 Jan 7.

PMID:
24398046
[PubMed - in process]
9.

Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.

Witzig TE, Maurer MJ, Stenson MJ, Allmer C, Macon W, Link B, Katzmann JA, Gupta M.

Am J Hematol. 2014 Apr;89(4):417-22. doi: 10.1002/ajh.23658. Epub 2014 Feb 10.

PMID:
24382707
[PubMed - indexed for MEDLINE]
10.

Isotope-labelled urea to test colon drug delivery devices in vivo: principles, calculations and interpretations.

Maurer MJ, Schellekens RC, Wutzke KD, Stellaard F.

Isotopes Environ Health Stud. 2013;49(4):473-91. doi: 10.1080/10256016.2013.803099.

PMID:
24313370
[PubMed - in process]
11.

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL.

PLoS One. 2013 Nov 14;8(11):e80063. doi: 10.1371/journal.pone.0080063. eCollection 2013.

PMID:
24244610
[PubMed - in process]
Free PMC Article
12.

APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.

Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg AL, Cunningham JM, Shridhar V, Bell DA, April C, Bentley D, Bibikova M, Cheetham RK, Fan JB, Grocock R, Humphray S, Kingsbury Z, Peden J, Chien J, Swisher EM, Hartmann LC, Kalli KR, Goode EL, Sicotte H, Kaufmann SH, Harris RS.

Cancer Res. 2013 Dec 15;73(24):7222-31. doi: 10.1158/0008-5472.CAN-13-1753. Epub 2013 Oct 23.

PMID:
24154874
[PubMed - indexed for MEDLINE]
13.

Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.

Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Cerhan JR, Novak AJ, Ansell SM.

Clin Cancer Res. 2013 Dec 15;19(24):6812-9. doi: 10.1158/1078-0432.CCR-13-1879. Epub 2013 Oct 18.

PMID:
24141626
[PubMed - in process]
14.

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Ghesquières H, Maurer MJ, Casasnovas O, Ansell SM, Larrabee BR, Lech-Maranda E, Novak AJ, Borrel AL, Slager SL, Brice P, Allmer C, Brion A, Ziesmer SC, Morschhauser F, Habermann TM, Gaillard I, Link BK, Stamatoullas A, Fermé C, Dogan A, Macon WR, Audouin J, Cerhan JR, Salles G.

Cytokine. 2013 Nov;64(2):523-31. doi: 10.1016/j.cyto.2013.08.002. Epub 2013 Sep 3.

PMID:
24008079
[PubMed - indexed for MEDLINE]
15.

Survival prediction based on inherited gene variation analysis.

Cicek MS, Maurer MJ, Goode EL.

Methods Mol Biol. 2013;1049:53-64. doi: 10.1007/978-1-62703-547-7_5.

PMID:
23913208
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR.

J Clin Oncol. 2013 Sep 10;31(26):3272-8. doi: 10.1200/JCO.2012.48.3990. Epub 2013 Jul 29.

PMID:
23897955
[PubMed - indexed for MEDLINE]
17.

Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer.

Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, Knutson KL, Block MS.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1730-5. doi: 10.1158/1055-9965.EPI-12-1368. Epub 2013 Jul 22.

PMID:
23878295
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.

Charbonneau B, Wang AH, Maurer MJ, Asmann YW, Zent CS, Link BK, Ansell SM, Weiner GJ, Ozsan N, Feldman AL, Witzig TE, Cunningham JM, Dogan A, Habermann TM, Slager SL, Novak AJ, Cerhan JR.

Cancer Immunol Immunother. 2013 Sep;62(9):1475-84. doi: 10.1007/s00262-013-1452-4. Epub 2013 Jun 28.

PMID:
23812490
[PubMed - indexed for MEDLINE]
19.

Bowel perforation in intestinal lymphoma: incidence and clinical features.

Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, Witzig TE.

Ann Oncol. 2013 Sep;24(9):2439-43. doi: 10.1093/annonc/mdt188. Epub 2013 May 22.

PMID:
23704194
[PubMed - indexed for MEDLINE]
20.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ.

Am J Hematol. 2013 Jul;88(7):589-93. doi: 10.1002/ajh.23460. Epub 2013 Jun 12.

PMID:
23619698
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk